Anti‐β‐sheet conformational monoclonals safely reduced pathology in TgSwDI/apoE2, 3 and 4 AD mouse models

We have shown that peripherally infused AβComAbs, IgMs GW-23B7 and WG-3D7 reduce, independently of all the human ApoE allotypes, soluble oligomeric and deposited vascular and parenchymal Aβ pathology by an Aβ-sequence independent mechanism avoiding ADCC induced microhemorrhages or inflammation. Our preclinical data testing the therapeutic efficacy of IgMs GW-23B7 and WG-3D7 in multiple AD/apoE models suggests that they could be safely translated to human AD clinical trials with a minimal possibility of ARIA or autoimmune toxicity complications.